Topical Melatonin for Androgenetic Alopecia

Verdict: Weak evidence; not a proven hair-loss treatment

Topical melatonin shows only a thin, directionally positive signal for androgenetic alopecia and is not an established treatment. It should not be relied on in place of proven options like minoxidil or finasteride.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The evidence base is small and low in quality, which is why this lands at a weak grade. The only placebo-controlled trial is Fischer 2004 (PMID 14996107), a double-blind pilot of just 40 women, with an androgenetic-alopecia subgroup of only about 12. It found a significant rise in occipital anagen (growing-phase) hair versus placebo (P=0.012), but a 2005 critical appraisal (PMID 16181483) flagged the tiny sample, mixed population, and multiple comparisons as reasons not to read it as proof of clinical benefit.

A later 2012 author review (PMID 23766606) reported larger gains of roughly 29 to 41 percent in hair density, but these came from open-label and observational studies run by an investigator tied to the product, so the bias risk is high. A 2025 network meta-analysis (PMID 41051009) placed topical melatonin only as a non-first-line over-the-counter alternative, ranking it below conventional therapies. No large, multicenter placebo-controlled RCT exists.

Regulators and clinics do not back it. The FDA has approved no topical melatonin hair product and notes there is "no basis to conclude that melatonin is GRAS," while the UK NHS lists only finasteride and minoxidil as the main treatments for male pattern baldness. Major bodies such as the NIH and leading clinics simply do not address it. Most studies here are industry-funded, reinforcing caution.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.54
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.539
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial
PMID: 14996107 2004 RCT (double-blind, placebo-controlled, pilot) n = 40
Finding: Topical melatonin significantly increased the anagen hair rate in occipital hair of women with androgenetic alopecia compared with placebo (P=0.012); in diffuse alopecia, a significant increase was seen in frontal hair (P=0.046). First in-vivo human evidence that topically applied melatonin might influence hair growth, possibly via induction of the anagen phase. Pilot study, small AGA subgroup (n=12 AGA of 40 total).
🟠 Limited quality ⚠️ Industry-funded Effect size: Occipital anagen rate increase vs placebo, P=0.012 (AGA subgroup)
View on PubMed
Is melatonin useful in alopecia: critical appraisal of a randomized trial?
PMID: 16181483 2005 Critical Appraisal / Commentary (letter)
Finding: Critical appraisal raising methodological concerns about the Fischer 2004 pilot RCT (small sample, mixed AGA/diffuse alopecia population, multiplicity of comparisons / subgroup testing), cautioning against over-interpreting the positive anagen-rate result as evidence of clinical efficacy.
View on PubMed
Topical melatonin for treatment of androgenetic alopecia
PMID: 23766606 2012 Review / pooled clinical studies summary (pharmacodynamic and pre-post observational studies)
Finding: Author summary reports topical melatonin associated with increased hair density (e.g., ~29% and ~41% over 6 months in men subsets), reduced positive hair-pull test rates, and reduced severity of alopecia, with good safety and tolerability. However, evidence is largely from open-label / pre-post / observational designs (NOT placebo-controlled RCTs), and the article is authored by an investigator associated with the melatonin solution — high risk of bias; cannot establish efficacy.
🟠 Limited quality ⚠️ Industry-funded Effect size: Reported ~29-41% hair density increase over 6 months (uncontrolled observational subsets)
View on PubMed
Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study
PMID: 41051009 2025 Network Meta-Analysis
Finding: Network meta-analysis confirmed efficacy of conventional treatments (oral dutasteride, topical/oral minoxidil, oral/topical finasteride) and provided guidance on relative efficacy of alternative agents including topical melatonin and topical rosemary oil. Among topical OTC agents, minoxidil 5% twice daily was most effective; topical melatonin is positioned as a non-first-line alternative, not superior to conventional therapy.
Effect size: Not separately quantified for topical melatonin in retrievable text; melatonin listed among alternative comparators, conventional therapies remain superior
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
no basis to conclude that melatonin is GRAS source↗
L4b EU EFSA
Not addressed
melatonin and reduction of sleep onset latency source↗
L4c UK NHS
Not addressed
Most hair loss does not need treatment ... Finasteride and minoxidil are the main treatments for male pattern baldness. source↗
L4d TW TFDA / 衛福部
Against
標示含melatonin(褪黑激素)之產品應以藥品管理 source↗
L5a NIH Office of Dietary Supplements
Not addressed
short-term use of melatonin supplements appears to be safe source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-androgenetic-alopecia-INT-topical-melatonin-001 繁體中文版 →